Dyne Therapeutics Inc (NASDAQ: DYN) Stock Dropped -7.55% Over A Month – Are There Any Chances Of Growth?

During the last session, Dyne Therapeutics Inc (NASDAQ:DYN)’s traded shares were 3.01 million, with the beta value of the company hitting 1.16. At the end of the trading day, the stock’s price was $10.78, reflecting an intraday loss of -0.74% or -$0.08. The 52-week high for the DYN share is $47.45, that puts it down -340.17 from that peak though still a striking 41.0% gain since the share price plummeted to a 52-week low of $6.36. The company’s market capitalization is $1.23B, and the average intraday trading volume over the past 10 days was 3.39 million shares, and the average trade volume was 2.66 million shares over the past three months.

Dyne Therapeutics Inc (DYN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.27. DYN has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 7 recommend a Buy rating for it.

Dyne Therapeutics Inc (NASDAQ:DYN) trade information

Dyne Therapeutics Inc (DYN) registered a -0.74% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.74% in intraday trading to $10.78, hitting a weekly high. The stock’s 5-day price performance is -26.01%, and it has moved by -7.55% in 30 days. Based on these gigs, the overall price performance for the year is -67.40%. The short interest in Dyne Therapeutics Inc (NASDAQ:DYN) is 25.53 million shares and it means that shorts have 10.06 day(s) to cover.

The consensus price target of analysts on Wall Street is $46, which implies an increase of 76.57% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $34 and $48 respectively. As a result, DYN is trading at a discount of -345.27% off the target high and -215.4% off the low.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -59.45%. While earnings are projected to return -16.29% in 2025, the next five years will return 0.35% per annum.

DYN Dividends

Dyne Therapeutics Inc is due to release its next quarterly earnings on 2025-May-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

The next largest institutional holding, with 7.85 million shares, is of FCPM III SERVICES B.V.’s that is approximately 8.4808% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $276.86 million.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.